Troxacitabine in leukemia

Hematology

Volumn 11, Issue 5-6, 2006, Pages 321-329

  Swords, Ronan ^a   Apostolidou, Effrosyni ^b   Giles, Francis ^b  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; IMATINIB; LAMIVUDINE; OXYGEN; PREDNISOLONE; TOPOTECAN; TROXACITABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTIVIRAL ACTIVITY; BLISTER; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CARDIOTOXICITY; CELLULITIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOTOXICITY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; ENANTIOMER; ERYTHEMA; GRANULOCYTIC SARCOMA; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HEPATITIS; HERPES LABIALIS; HUMAN; HYPERPIGMENTATION; LEUKEMIA; MALAISE; MONOTHERAPY; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PERIRENAL ABSCESS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SEIZURE; SEPTICEMIA; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SKIN EXFOLIATION; SKIN PAIN; SKIN TIGHTNESS; SKIN TOXICITY; SOFT TISSUE DISEASE; STEREOCHEMISTRY; STOMATITIS; STROKE; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTINEOPLASTIC AGENTS; CYTOSINE; DIOXOLANES; HUMANS; LEUKEMIA; TREATMENT OUTCOME;

EID: 34250709528     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245330601027316     Document Type: Review

References (41)

1. Mansour, TS, Jin, H. and Wang, W. (1995) Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2′-deoxy-3′-oxa-4′-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem, 38, pp. 1-4.
2. Giles, FJ (2002) Troxacitabine-based therapy of refractory leukemia. Expert Rev Anticancer Ther, 2, pp. 261-266.
3. Balzarini, J., Wedgwood, O. and Kruining, J. (1996) Anti-HIV and anti-HBV activity and resistance profile of 2′,3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109. Biochem Biophys Res Commun, 225, pp. 363-369.
4. Mar, EC, Chu, CK and Lin, JC (1995) Some nucleoside analogs with anti-human immunodeficiency virus activity inhibit replication of Epstein-Barr virus. Antiviral Res, 28, pp. 1-11.
5. Coates, JA, Cammack, N. and Jenkinson, HJ (1992) (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother, 36, pp. 733-739.
6. Grove, KL, Guo, X., Liu, SH, Gao, Z., Chu, CK and Cheng, YC (1995) Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration. Cancer Res, 55, pp. 3008-3011.
7. Grove, KL and Cheng, YC (1996) Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res, 56, pp. 4187-4191.
8. Siu, LL, Attardo, G. and Izbicka, E. (1998) Activity of (-)-2′-deoxy-3′-oxacytidine (BCH-4556) against human tumor colony-forming units. Ann Oncol, 9, pp. 885-891.
9. Kadhim, SA, Bowlin, TL and Waud, WR (1997) Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res, 57, pp. 4803-4810.
10. Gourdeau, H., Clarke, ML and Ouellet, F. (2001) Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. Cancer Res, 61, pp. 7217-7224.
11. Gourdeau, H., Bibeau, L., Ouellet, F., Custeau, D., Bernier, L. and Bowlin, T. (2001) Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity. Cancer Chemother Pharmacol, 47, pp. 236-240.
12. Gourdeau, H., Leblond, L. and Hamelin, B. (2004) Species differences in troxacitabine pharmacokinetics and pharmacodynamics: Implications for clinical development. Clin Cancer Res, 10, pp. 7692-7702.
13. Owens, JK, Shewach, DS, Ullman, B. and Mitchell, BS (1992) Resistance to 1-beta-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res, 52, pp. 2389-2393.
14. de Bono, JS, Stephenson Jr., J. and Baker, SD (2002) Troxacitabine, an -stereoisomeric nucleoside analog, on a five-times-daily schedule: A phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol, 20, pp. 96-109.
15. Krishnan, P., Lam, W., Liou, JY, Dutschman, G. and Cheng, YC (2002) Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: Selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem, 277, pp. 5453-5459.
16. Krishnan, P., Gullen, EA, Lam, W., Dutschman, GE, Grill, SP and Cheng, YC (2003) Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of -nucleoside analogs, a new class of anticancer and antiviral agents. J Biol Chem, 278, pp. 36726-36732.
17. Moore, LE, Boudinot, FD and Chu, CK (1997) Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats. Cancer Chemother Pharmacol, 39, pp. 532-536.
18. Kukhanova, M., Liu, SH, Mozzherin, D., Lin, TS, Chu, CK and Cheng, YC (1995) L- and D-enantiomers of 2′,3′-dideoxycytidine 5′-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J Biol Chem, 270, pp. 23055-23059.
19. Grant, S. (1998) Ara-C: Cellular and molecular pharmacology. Adv Cancer Res, 72, pp. 197-233.
20. Weitman, S., Marty, J., Jolivet, J., Locas, C. and Von Hoff, DD (2000) The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin Cancer Res, 6, pp. 1574-1578.
21. Schwartz, PM, Haggerty, JG and Cheng, YC (1998) Beta-L-1,3-dioxolane-cytidine: A novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro. Skin Pharmacol Appl Skin Physiol, 11, pp. 207-213.
22. Rabbani, SA, Harakidas, P., Bowlin, T. and Attardo, G. (1998) Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo. Cancer Res, 58, pp. 3461-3465.
23. Kim, TE, Park, SY, Hsu, CH, Dutschman, GE and Cheng, YC (2004) Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines. Mol Pharmacol, 66, pp. 285-292.
24. Gati, WP, Paterson, AR and Belch, AR (1998) Es nucleoside transporter content of acute leukemia cells: Role in cell sensitivity to cytarabine (araC). Leuk Lymphoma, 32, pp. 45-54.
25. Bouffard, DY, Jolivet, J. and Leblond, L. (2003) Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells. Cancer Chemother Pharmacol, 52, pp. 497-506.
26. Orsolic, N., Giles, FJ and Gourdeau, H. (2004) Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: Preclinical evaluation. Br J Haematol, 124, pp. 727-738.
27. Belanger, K., Moore, M. and Baker, SD (2002) Phase I and pharmacokinetic study of novel -nucleoside analog troxacitabine given as a 30-minute infusion every 21 days. J Clin Oncol, 20, pp. 2567-2574.
28. Canova, A., Yee, L. and Baker, SD (1999) A phase I and pharmacokinetic study of beta-L-dioxalo-cytidine (BCH-4556) administered weekly for 3 weeks every 28 days. Proc Am Soc Clin Oncol, 18, p. 197.
29. Stephenson, J., Baker, S. and Aylesworth, C. (1998) A phase I and pharmacokinetic study of BCH-4556, a novel -nucleoside antimetabolite, on a daily × 5 day every 21-day schedule in patients with solid neoplasms. Ann Oncol, 9, p. 156.
30. Giles, FJ, Cortes, JE and Baker, SD (2001) Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol, 19, pp. 762-771.
31. Giles, FJ, Garcia-Manero, G. and Cortes, JE (2002) Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol, 20, pp. 656-664.
32. Lee, CK and Rowinsky, EK (2006) Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin Cancer Res, 12, pp. 2158-2165.
33. Giles, FJ, Feldman, EJ and Roboz, GJ (2003) Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase. Leuk Res, 27, pp. 1091-1096.
34. Alvarado, Y., Kantarjian, HM, Cortes, JE, Apostolidou, E., Bivins, C. and Giles, FJ (2002) Troxacitabine activity in extramedullary myeloid leukemia. Hematology, 7, pp. 179-185.
35. Giles, FJ, Faderl, S. and Thomas, DA (2003) Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. J Clin Oncol, 21, pp. 1050-1056.
36. Giles, FJ, Kantarjian, HM and Cortes, JE (2003) Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol, 21, pp. 1722-1727.
37. Giles, F., Garcia-Manero, G., O'Brien, S., Estey, E. and Kantarjian, H. (2002) Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome. Acta Haematol, 108, pp. 164-167.
38. Roboz, GR, Giles, FJ and Ritchie, EK (2006) Phase I/II study of troxacitabine administered by continuous infusion in patients with refractory acute myeloid leukemia. J Clin Oncol
39. Giles, F., O'Brien, S. and Cortes, J. (2005) Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer, 104, pp. 547-554.
40. Lopez, A., Wallace, L. and Dorr, R. (1999) Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol, 44, pp. 303-306.
41. Vukelja, SJ, Lombardo, FA, James, WD and Weiss, RB (1989) Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med, 111, pp. 688-689.